3SBIO(01530.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.15 billion, YoY decrease of 15.58%

NewTimeSpace News: August 20, 2026, 3SBIO(01530.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 4.53 billion, increased by 3.91% YoY; Net Profit stood at CNY 1.21 billion, YoY decrease of 12.86%; Profit Attributable to Shareholders stood at CNY 1.15 billion, YoY decrease of 15.58%; Basic Earnings Per Share (EPS) stood at CNY 0.45.

In terms of profitability, 3SBIO Gross Profit changed from CNY 3.72 billion in the same period last year to CNY 3.79 billion in the current period, increased by CNY 78.78 million; gross profit margin changed from 85.31% in the same period last year to 83.84% in the current period, decreased by 1.47 percentage points; net profit changed from CNY 1.39 billion in the same period last year to CNY 1.21 billion in the current period, decreased by CNY 178.51 million; net profit margin changed from 31.88% in the same period last year to 26.74% in the current period, decreased by 5.14 percentage points. 

In terms of earnings quality, 3SBIO Operating Profit changed from CNY 1.65 billion in the same period last year to CNY 1.47 billion in the current period, decreased by CNY 183.64 million; Operating Profit Margin changed from 37.92% in the same period last year to 32.44% in the current period, decreased by 5.49 percentage points. 

In terms of financial soundness, 3SBIO Debt-to-Asset Ratio changed from 20.51% in the same period last year to 13.53% in the current period, decreased by 6.98 percentage points; Total Equity changed from CNY 18.943 billion in the same period last year to CNY 30.765 billion in the current period, increased by CNY 11.82 billion; Current Liabilities changed from CNY 4.2 billion in the same period last year to CNY 3.41 billion in the current period, decreased by CNY 795.45 million; Quick Ratio changed from 2.12 in the same period last year to 5.75 in the current period, increased by 3.63 percentage points. 

In terms of R&D investment focus, 3SBIO R&D Expenses changed from CNY 547.52 million in the same period last year to CNY 683.85 million in the current period, increased by CNY 136.33 million; R&D to Total Revenue Ratio changed from 12.57% in the same period last year to 15.11% in the current period, increased by 2.54 percentage points.

By the close of trading on August 20, 2026, 3SBIO(01530) saw a loss of 1.14% in its share price, closing at HKD 16.5. The full-day turnover stood at HKD 998.92 million, showing significant volume increase, with the latest market capitalization at HKD 41.74 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.